Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 7 Hematologic Neoplasms 7 Graft vs Host Disease 5 Gliosarcoma 5 Glioblastoma 5 Brain Neoplasms 5 Prostatic Neoplasms 4 Myelodysplastic Syndromes 4 Lymphoma, Non-Hodgkin 4 Waldenstrom Macroglobulinemia 3 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Hodgkin Disease 3 Carcinoma, Non-Small-Cell Lung 3 Tuberous Sclerosis 2 Oligodendroglioma 2 Neurofibrosarcoma 2 Myeloproliferative Disorders 2 Lymphoma, Mantle-Cell 2 Lymphoma 2 Lung Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Glioma 2 Burkitt Lymphoma 2 Bronchiolitis Obliterans Syndrome 2

Interventions

pembrolizumab 30 Nivolumab 15 Paclitaxel 13 Cyclophosphamide 12 Carboplatin 12 sacituzumab govitecan 8 Cisplatin 8 Capecitabine 7 130-nm albumin-bound paclitaxel 7 Gemcitabine 6 fludarabine 5 durvalumab 5 avelumab 5 atezolizumab 5 Magnetic Resonance Spectroscopy 5 Ipilimumab 5 Biopsy 5 camrelizumab 4 Specimen Handling 4 Interleukin-2 4 Injections 4 Immune Checkpoint Inhibitors 4 Docetaxel 4 toripalimab 3 talazoparib 3 Leucovorin 3 Everolimus 3 Clinical Trials, Phase II as Topic 3 Bevacizumab 3 yeast-CEA vaccine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Triple Negative Breast Neoplasms × Sirolimus × Clear all

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡